IMF TV

From our weekly series “Ask Dr. Durie” to comprehensive news from key cancer medical conferences around the world, IMF-TV is your all-access ticket to critical myeloma research, patient education and guidance. Check back often for regularly updated content. 

Jun
14
Stockholm 2018: Status of MRD Testing
​In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about the status of minimal residual (MRD) testing with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Sagar Lonial(...)
Jun
14
Stockholm 2018: CAR T-cell Therapy
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about CAR T-cell therapy with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Sagar Lonial (Emory University, Atlanta(...)
Jun
14
Stockholm 2018: New Drugs in Multiple Myeloma
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about new drugs and drug combinations in the myeloma treatment landscape with Dr. Joseph Mikhael (IMF Chief Medical Officer(...)
Jun
14
Stockholm 2018: Cost of Care
Drs. Brian GM Durie, Joseph Mikhael, and Sagar Lonial discuss the cost of care for multiple myeloma.
Jun
14
Stockholm 2018: The Role of CRISPR Gene Editing
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about the role of CRISPR gene-editing in the landscape of multiple myeloma treatment with Dr. Joseph Mikhael (IMF Chief(...)
Jun
14
How does minimal residual disease (MRD) testing affect treatment decisions?
In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next steps in a myeloma patient’s treatment.